Last: | $ |
---|---|
Change Percent: | -0.55% |
Open: | $1.97 |
Close: | $1.80 |
High: | $1.97 |
Low: | $1.78 |
Volume: | 14,934 |
Last Trade Date Time: | 09/02/2019 04:51:01 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $1.97 | $1.80 | $1.97 | $1.78 | 14,934 | 09-02-2019 |
$ | $1.97 | $1.80 | $1.97 | $1.78 | 14,684 | 08-30-2019 |
$ | $1.938 | $1.81 | $1.938 | $1.78 | 31,067 | 08-29-2019 |
$ | $1.893 | $1.86 | $1.9002 | $1.81 | 11,903 | 08-28-2019 |
$ | $1.87 | $1.87 | $1.99 | $1.83 | 38,608 | 08-27-2019 |
$ | $1.92 | $1.90 | $2.00 | $1.90 | 20,549 | 08-26-2019 |
$ | $1.90 | $1.93 | $2.06 | $1.8965 | 57,868 | 08-23-2019 |
$ | $1.92 | $1.9223 | $1.9599 | $1.8301 | 32,984 | 08-22-2019 |
$ | $1.92 | $1.9196 | $1.98 | $1.79 | 35,505 | 08-21-2019 |
$ | $1.94 | $1.9201 | $1.9946 | $1.90 | 36,024 | 08-20-2019 |
$ | $1.88 | $1.93 | $2.07 | $1.7906 | 70,320 | 08-19-2019 |
$ | $2.00 | $1.89 | $2.00 | $1.705 | 89,596 | 08-16-2019 |
$ | $2.00 | $1.90 | $2.07 | $1.82 | 58,505 | 08-15-2019 |
$ | $2.00 | $1.85 | $2.00 | $1.80 | 59,333 | 08-14-2019 |
$ | $1.84 | $1.89 | $1.959 | $1.81 | 47,364 | 08-13-2019 |
$ | $2.02 | $1.86 | $2.02 | $1.69 | 70,256 | 08-12-2019 |
$ | $2.19 | $1.99 | $2.19 | $1.91 | 176,184 | 08-09-2019 |
$ | $2.37 | $2.22 | $2.44 | $2.10 | 1,238,854 | 08-08-2019 |
$ | $2.06 | $2.07 | $2.11 | $2.05 | 47,079 | 08-07-2019 |
$ | $2.15 | $2.05 | $2.15 | $2.00 | 37,626 | 08-06-2019 |
News, Short Squeeze, Breakout and More Instantly...
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...